To the full analysis
West Pharmaceutical Services stock: growth
WSTWest Pharmaceutical Services reported $3.07B in revenue for fiscal 2025, up 6.3% on the prior year, up 7.4% a year on average over up to five years.
Daily figure as of 12 Nov 2026
Revenue (Annual rate)
6.6%
per year from 2006 to 2025, per share 5.9%
Earnings (Annual rate)
11.1%
per year from 2006 to 2025, per share 10.4%
Free cash flow (Annual rate)
12.1%
per year from 2006 to 2025, per share 11.4%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 7.4% | 8.2% | 6.6% |
| Revenue per share | 7.9% | 8.2% | 5.9% |
| Earnings | 7.4% | 17.8% | 11.1% |
| Earnings per share | 7.9% | 17.8% | 10.4% |
| Free cash flow | 9.5% | 19.2% | 12.1% |
| Free cash flow per share | 10.0% | 19.2% | 11.4% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $913.3M | $67.1M | $53.5M |
| 2007 | $1.02B | $70.7M | −$200K |
| 2008 | $1.05B | $86M | −$4.1M |
| 2009 | $1.06B | $72.6M | $29.9M |
| 2010 | $1.1B | $65.3M | $64.5M |
| 2011 | $1.19B | $75.5M | $33.9M |
| 2012 | $1.27B | $80.7M | $55.4M |
| 2013 | $1.37B | $112.3M | $64.7M |
| 2014 | $1.42B | $127.1M | $70.8M |
| 2015 | $1.4B | $95.6M | $80.8M |
| 2016 | $1.51B | $143.6M | $49.2M |
| 2017 | $1.6B | $150.7M | $132.5M |
| 2018 | $1.72B | $206.9M | $183.9M |
| 2019 | $1.84B | $241.7M | $240.8M |
| 2020 | $2.15B | $346.2M | $298.1M |
| 2021 | $2.83B | $661.8M | $330.6M |
| 2022 | $2.89B | $585.9M | $439.4M |
| 2023 | $2.95B | $593.4M | $414.5M |
| 2024 | $2.89B | $492.7M | $276.4M |
| 2025 | $3.07B | $493.7M | $468.9M |
Revenue by segment
How West Pharmaceutical Services, Inc. makes its money and how that has shifted. Names are as the company reports them.
- Proprietary Products81%
- Contract Manufactured Products19%
Figures as a table
| 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|
| Proprietary Products | $2.32B | $2.41B | $2.4B | $2.33B | $2.49B | 81.1% |
| Contract Manufactured Products | $514.7M | $480.4M | $552.5M | $558.7M | $582M | 18.9% |
| Total revenue | $2.83B | $2.89B | $2.95B | $2.89B | $3.07B | 100% |
Revenue by region
Where West Pharmaceutical Services, Inc. generates its revenue.
- United States43%
- Germany12%
- Ireland11%
- France7%
- Other26%
“Other” combines smaller regions with revenue the company does not assign to a region.
Figures as a table
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share 2025 | |
|---|---|---|---|---|---|---|---|---|
| United States | $814.7M | $975.6M | $1.2B | $1.29B | $1.24B | $1.23B | $1.33B | 43.3% |
| Germany | $236.3M | $282.1M | $474.3M | $398.7M | $406.1M | $372.5M | $380.3M | 12.4% |
| Ireland | $173.8M | $226M | $247.6M | $240.3M | $285.7M | $323.2M | $333.3M | 10.8% |
| France | $150.6M | $172.7M | $213M | $237.9M | $282.9M | $242.2M | $226.6M | 7.4% |
| Other | $468.2M | $490.3M | $697.8M | $722.1M | $737.9M | $724M | $803.9M | 26.2% |
| Total revenue | $1.84B | $2.15B | $2.83B | $2.89B | $2.95B | $2.89B | $3.07B | 100% |
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 10 Apr 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.